Veterinary Dermatology Drugs Market Report 2026

The veterinary dermatology drugs market size has grown rapidly in recent years. It will grow from $9.54 billion in 2025 to $10.64 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to limited awareness of animal dermatology, rising incidence of parasitic infections, adoption of traditional antifungal and antibacterial drugs, growth of companion animal ownership, development of basic topical treatments.

The veterinary dermatology drugs market size is expected to see rapid growth in the next few years. It will grow to $16.37 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to advancements in precision dermatology drugs, increasing use of combination therapies, growing companion animal healthcare expenditure, rising prevalence of allergic skin conditions, expansion of hospital and retail pharmacy distribution channels. Major trends in the forecast period include rising prevalence of skin infections in companion animals, increasing demand for topical veterinary drugs, growth in online veterinary pharmacies, expansion of injectable and oral dermatology treatments, development of targeted antiparasitic therapies.

The rising number of pet owners is expected to drive growth in the veterinary dermatology drugs market in the coming years. Pet owners are individuals who own or adopt companion animals. The increase in pet ownership is fueled by a growing desire for companionship to cope with busy lifestyles and social isolation, leading more households to view pets as emotional support and family members. Veterinary dermatology drugs support pet owners by effectively treating skin conditions in their animals, improving comfort, health, and overall quality of life. For example, in 2023, according to Shelter Animals Count, a US-based non-governmental organization, 4.8 million animals in shelters and rescues were adopted into loving homes. Therefore, the growing number of pet owners is propelling the veterinary dermatology drugs market.

Leading players in the veterinary dermatology drugs market are focusing on developing innovative therapies, such as Janus kinase (JAK) inhibitors and targeted oral treatments, to enhance therapeutic efficacy and convenience for canine patients. JAK inhibitors are targeted therapies that block intracellular signaling pathways involved in allergic inflammation and pruritus, disrupting the itch-scratch cycle and reducing disease severity. Once-daily oral therapies provide consistent dosing and ease of administration for long-term management of chronic dermatological conditions. For instance, in September 2024, Elanco Animal Health Incorporated, a US-based global animal health company, announced that the U.S. Food and Drug Administration (FDA) approved Zenrelia (ilunocitinib tablets) for the treatment of allergic and atopic dermatitis in dogs. Zenrelia, a once-daily oral JAK inhibitor, offers a safe, highly effective, and convenient treatment option, demonstrating reduced rebound itch and improved clinical remission rates compared to existing market alternatives, highlighting the growing emphasis on targeted and patient-friendly innovations in veterinary dermatology.

In January 2023, Animal Dermatology Group, Inc., a US-based veterinary dermatology firm, acquired Golden Gate Veterinary Specialists for an undisclosed sum. This acquisition is intended to enhance Animal Dermatology Group's ability to offer specialized veterinary services by integrating Golden Gate Veterinary Specialists. This move will expand their team of over 80 veterinary specialists and reinforce their commitment to providing high-quality, individualized care in dermatology, oncology, and internal medicine to meet the increasing demand for outpatient veterinary specialty services. Golden Gate Veterinary Specialists is a US-based practice specializing in dermatological and surgical care.

Major companies operating in the veterinary dermatology drugs market are Elanco Animal Health Inc., Merck & Co. Inc., Zoetis Inc., Vetoquinol SA, Ceva Santé Animale, Virbac S.A., Bimeda Inc., IDEXX Laboratories Inc., SavaVet, Vetmedica, Mars Incorporated, Kindred Biosciences, Bayer Animal Health, Boehringer Ingelheim Vetmedica, Dechra Pharmaceuticals PLC, Norbrook Laboratories Limited, Heska Corporation, Biogénesis Bagó, Nexvet, Aratana Therapeutics, Phibro Animal Health Corporation, HIPRA, Kyoritsu Seiyaku Corporation.

North America was the largest region in the veterinary dermatology drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the veterinary dermatology drugs market report forecast period. The regions covered in the veterinary dermatology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary dermatology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the veterinary dermatology drugs market by increasing the cost of imported antifungal, antibacterial, and antiparasitic drugs, particularly affecting companion animal segments in north america and europe. Segments such as topical treatments and advanced injectable formulations face higher import costs. Positive impacts include boosting domestic drug manufacturing, encouraging innovation in cost-effective formulations, and reducing dependency on global supply chains.

The veterinary dermatology drugs market research report is one of a series of new reports that provides veterinary dermatology drugs market statistics, including veterinary dermatology drugs industry global market size, regional shares, competitors with a veterinary dermatology drugs market share, detailed veterinary dermatology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary dermatology drugs industry. This veterinary dermatology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary dermatology drugs are medications specifically formulated to address skin conditions in animals, such as infections, allergies, and parasites. These treatments are utilized to relieve itching, reduce inflammation, and facilitate skin healing. By addressing dermatological issues, these drugs contribute to enhancing the overall health and comfort of affected animals.

The primary categories of veterinary dermatology drugs include antifungal drugs, antibacterial drugs, and antiparasitic drugs. Antifungals are pharmaceuticals that inhibit the growth of fungi responsible for infections commonly affecting the skin, hair, and nails of animals. These drugs are administered through various routes, including topical, injectable, and oral methods. The target recipients of these medications are diverse, ranging from companion animals to livestock. The drugs are utilized for indications such as parasitic infections and allergic reactions. Distribution channels for veterinary dermatology drugs encompass retail outlets, hospital pharmacies, and online platforms.

The veterinary dermatology drugs market consists of sales of dicloxacillin, erythromycin, tetracycline, and retinoids, which are naturally occurring and synthetic compounds with vitamin A activity. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.